In unrelated cord blood (UCB) transplantation, survival has been shown to correlate with the degree of HLA matching. Thus, to extend transplant access to different ethnic backgrounds, many western UCB transplantation banks now encourage donation from non-Caucasians. Until recently, Saudi Arabia did not have a national UCB bank. In this study we report our experience in UCB transplantation in children using units procured from western cord blood banks. A total of 97 children underwent unrelated UCB transplantation at King Faisal Specialist Hospital and Research Center (KFSHRC), of which 95 were of Arab ethnicity. A total of 30 patients had malignant disorders, 25 patients had non-malignant hematological disorders and 42 patients had inborn errors. Conditioning was according to disease, with six patients receiving reduced-intensity regimens. In all, 46 patients received one-Ag-mismatched units and 51 received twoAg-mismatched units. Engraftment occurred in 93% of patients, the 100-TRM was 15%, acute GVHD developed in 20% of patients and chronic GVHD occurred in 9% of patients. The 5-year OS and EFS estimates were 52 and 43%, respectively. The search for UCB transplantation units for Saudi patients in western banks yielded reasonably compatible units for our patients; the results are consistent with published data. Our data are encouraging for UCB transplant programs in countries in which there are no national UCB transplantation banks.
Introduction
Unrelated cord blood (UCB) transplantation is now an established viable option for many children who require allo-SCT but lack a suitable family donor. [1] [2] [3] [4] [5] [6] [7] [8] In UCB transplants, the degree of HLA matching has been closely associated with long-term survival. Thus, it is now a major goal of public cord blood banking to provide a large and diverse inventory of HLA typing to extend transplant access to racial and ethnic minorities. 9, 10 For transplant programs in countries in which no national BM registries or cord blood banks are established, the only available option is to search for suitable donors or UCB transplantation units in foreign registries and banks, but the diversity of the genetic background in different ethnicities around the world may diminish the probabilities of finding suitable matches. Thus, many such countries are now supporting the establishment of national cord blood banks to enhance the probability of finding suitable units for their nationals who need SCT but have no suitable matched family donor. [11] [12] [13] [14] In Saudi Arabia, there is currently no national donor program registry, and until September 2008 there was no national cord blood bank. The first case of UCB transplant in Saudi Arabia was performed in January 2003 at King Faisal Specialist Hospital and Research Center (KFSHRC), and until the opening of the Saudi National Bank, all the units were procured from western banks. In this study we report our experience.
Patients and methods

Patient characteristics
From January 2003 to December 2008, 97 pediatric patients underwent UCB transplantation at KFSHRC in Riyadh, Saudi Arabia. The characteristics of the patients are detailed in Table 1 . There were 39 female and 58 male patients. The median patient age at transplantation was 2.5 years (range 0.3-11.7 years) and the median patient weight at transplantation was 11.3 kg (range 4-41.5 kg). The patients were divided according to their underlying disease into three categories (Table 2) : 30 patients had malignant disorders, 25 patients had non-malignant hematological disorders and 42 patients had inborn errors (immune deficiency disorders or metabolic disorders). All patients received the transplant on a KFSHRC-Research Advisory Council-approved protocol. Of the 97 transplanted patients, 95 were of Arab ethnicity, with the majority being Saudi nationals. A total of 96 cord blood units were procured from western banks and one was procured from the National Saudi Cord Blood Bank after it became operational in September 2008. No problems were encountered in the shipment of the units from the international banks.
Conditioning regimens
The conditioning regimens used were tailored according to the underlying disease, and antithymocyte globulin (ATG) was included in the conditioning regimens of 96 patients. A total of six patients with primary immunodeficiency disorders (PIDs) received reduced-intensity conditioning (RIC) because they were deemed unfit to receive myeloablative conditioning (one patient had Wiskott-Aldrich disease, three patients had Omen's syndrome and two patients had SCID and all had co-morbid conditions). The 
GVHD prophylaxis
All patients received cyclosporin and a short course of prednisone and GCSF from day þ 1 until neutrophil engraftment.
Analysis end points
End points for analysis in this study included engraftment, GVHD and OS and EFS. To be evaluable for myeloid and plt engraftment, patients had to survive to day 28. Myeloid engraftment was defined as the first of 3 days of a sustained ANC 4500/mm 3 . Plt engraftment was defined as the first of three consecutive days of plt counts 420 000/mm 3 without plt transfusion in the preceding week. Donor chimerism was determined on peripheral blood on day 28 using the molecular STR analysis. STR was then repeated at regular intervals, every 4 months during the first year and then once in the second year. Patients suffering an event before 28 days were not evaluable for donor chimerism. Acute and chronic GVHD were defined according to standard criteria. Patients surviving to day 28 after transplant were evaluable for acute GVHD and those surviving beyond day 100 after transplant were evaluable for chronic GVHD. Events were defined as graft failure/rejection, leukemic relapse after engraftment or death.
Results
Characteristics of transplanted units
All patients received single cord blood units; 46 patients received one-Ag-mismatched units and 51 patients received two-Ag-mismatched units (22 of them had one class I and one class II mismatches, and 1 patient had two class II mismatches). The median pre-thaw cord blood total nucleated cell dose and CD34 þ cell dose were 9.7 Â 10 
Engraftment
As two patients died before reaching day 28, only 95 patients were evaluable for engraftment as defined above. In all, 88 patients engrafted (93%); the median time to neutrophil engraftment was 17 days (range 10-49 days) and the median time to plt engraftment was 41 days (range 15-161 days). In the group that received RIC, five of the six patients engrafted.
GVHD
A total of 95 patients were at risk for acute GVHD. Acute GVHD (grade II-IV) developed in 19 patients (20%), 12 of whom had severe-grade III and IV-GVHD (13%). The degree of HLA mismatching did not seem to influence the incidence of acute grade II-IV GVHD (9 in the one-Agmismatch group and 10 in the two-Ag-mismatch group). In all, 81 patients survived beyond day 100 and thus were at risk for chronic GVHD, and seven of them (9%) developed chronic GVHD (five limited and two extensive).
Other complications
Five patients developed veno-occlusive disease of the liver, which was severe and contributed to the demise of two patients. Hemorrhagic cystitis developed in 13 patients (13%), all of whom recovered with conservative management with hydration, bladder irrigation and/or intravesical prostaglandins. Fifty patients (52%) developed CMV infection.
Follow-up and survival
A total of 16 patients died within the first 100 days after SCT, and the mortality was treatment related in 15 patients (TRM of 15%); one patient died of recurrence of his leukemia. The median survival time from the time of SCT was 161 days (range 2-1912 days) and the median hospitalization duration for the transplant procedure was 39 days (range 2-391 days). The Kaplan-Meier estimates of OS and EFS for all patients at 5 years were 52 and 43%, respectively (Figures 1 and 2) . The degree of HLA mismatch did not seem to significantly affect the outcome, as the Kaplan-Meier estimates of OS for patients who received one-Ag-mismatched and those who received twoAg-mismatched units were 54 and 47% (P ¼ 0.24) respectively, and the corresponding estimates for EFS for the two groups, respectively, were 48 and 37% (P ¼ 0.1). However, the higher-level HLA match was associated with an improved EFS in patients with non-malignant hematological disorders, as the Kaplan-Meier estimate of EFS for those who had one-Ag-mismatched units was 57 vs 19% for patients who had two-Ag-mismatched units (P ¼ 0.06; Figure 3 ). The Kaplan-Meier estimates of OS at 5 years according to disease category were 53, 41 and 60% for patients with inborn errors, malignant disorders and nonmalignant hematological disorders, respectively (Figure 4) , and the corresponding estimates for EFS for the three groups, respectively, were 44, 38 and 44% ( Figure 5 ). In the malignant hematological disorders group, survival appeared better in patients with AML than in patients with ALL (although the difference did not reach statistical significance); the KS estimates for 5-year OS for the patients with AML and ALL, respectively, were 52 and 13% and the corresponding estimates for EFS were 47 and 13% (P ¼ 0.11). Out of the 32 patients with PID in the inborn errors group, a total of 15 patients succumbed to TRM (8 patients died within the first 100 days and 7 patients died subsequently), and at the time of this report 17 patients are alive and well with no evidence of disease. Of the six patients who received RIC (all with PID), five are alive and well with no evidence of disease; three have full chimerism and two have mixed chimerism. In total, 60 patients of the 97 patients are alive at the time of this report. The causes of death in the remaining patients were sepsis (10 patients), organ failure/acute respiratory distress syndrome (18 patients), leukemia relapse (7 patients), intracranial hemorrhage (1 patient) and pulmonary hemorrhage (1 patient). 
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Second transplants
In all, seven patients who failed to engraft after the first transplant received second UCB transplants, six because of primary total graft failure, and one because of partial graft failure. The patient with partial graft failure had leukocyte adherence deficiency. He engrafted his neutrophils but failed to engraft his plts and remained dependent on plt transfusion for 9 months, and hence the decision was made to perform a second UCB transplant. The median time from the first to the second UCB transplant was 2 months (range 1.4-21 months); as preparative regimens, three patients received Cytoxan/ATG/TBI, two patients received fludarabine/melphalan/ATG and two patients had only ATG. Four of these patients died (all four died of regimenrelated toxicity but had full donor engraftment and no evidence of disease at the time of death), and three patients remain alive after the second SCT (two fully engrafted and with no evidence of disease and one alive with disease). 9 and hence it is likely that the Arab ethnicity is underrepresented in the western cord blood banks. Many western banks now aim at recruiting nonCaucasian individuals for cord blood units and a recent study showed that some DRB1 alleles occurred at higher frequency in cord blood banks than unrelated donor registries, 14 likely because of increased recruitment of cord blood donation from ethnic minorities. In our study, 96 of the 97 reported patients received units from western cord blood banks, and 47% of the units were one-Ag mismatched. The Saudi National Cord Blood Bank mainly recruits from Saudi mothers, and we expect consequently that the future search for suitable unrelated cord blood units for Saudi patients in the local bank will yield a higher degree of HLA compatibility.
Discussion
The different genetic background of the transplanted units did not seem to adversely affect the outcome in our patients; our engraftment rate is 93% and our 100-TRM is 15%, conforming to already published data. 1, [3] [4] [5] [6] 15, 16 In the malignant disorder category, we report in this study an estimated OS and EFS of 41 and 38%, respectively, and others also have reported similar figures. 7, 9, 15 The degree of HLA disparity seemed to have an effect on the survival of patients with non-malignant hematological disorders, as has been shown by Gluckman et al. 3 in Fanconi anemia (FA) patients, although others failed to show such an effect in patients with severe aplastic anemia. 1 Because of the high rate of consanguinity in Saudi Arabia, there is a high incidence of hereditary BM disorders. In this study, 10 patients were transplanted for FA, and at the time of this report five of them are alive and fully engrafted, and one is alive with the disease despite a second transplant. Gluckman et al. 3 reported in a multiinstitutional study an OS of 40% in 93 patients with FA and showed that the addition of fludarabine had a positive effect on the outcome (OS of 50% in patients who received fludarabine vs 25% in those who did not). All of our patients received fludarabine but we found that the concomitant administration of BU (the first four patients) was associated with severe liver toxicity that contributed to the death of two patients.
Primary immunodeficiency disorders are another highly prevalent disease entity in Saudi Arabia due to consanguineous marriages. We report in this study a relatively large number of patients (32 patients), 17 of whom are long-term disease-free survivors; the reported survival rates in the literature are between 73 and 86%. 4, 5, 17 One health measure required by the ministry of health for all neonates in Saudi Arabia is the routine administration of the Bacille Calmette-Gue´rin vaccine after birth, and hence in the absence of a PID family history, many of these children are referred for allo-SCT and are critically ill with disseminated Tuberculosis after receiving this vaccine. The use of RIC may be particularly reasonable in this subset of patients because of the co-morbid conditions, but the available data on RIC in cord blood transplantation are, although encouraging, mostly based on single-center studies and are limited by the small number of patients and the short follow-up. [18] [19] [20] [21] In this series, five of the six patients with PID and those who received RIC are currently alive and well with no evidence of disease.
Our incidence of acute GVHD (20%) and of severe acute GVHD (13%) seemed to be similar to that reported in the literature. 22 Furthermore, the degree of HLA disparity did not affect the incidence of GVHD as has been previously shown by others. 23, 24 Some other studies have, however, shown some association with HLA disparity. 25, 26 Second cord blood transplants are associated with a high incidence of regimen-related morbidity and mortality even with reduced-intensity regimens. [27] [28] [29] [30] In this report, seven of our patients underwent second cord blood transplants and six of them engrafted successfully as shown by STR studies. Toxicity, however, was a major complication as four of our patients died of regimen-related toxicity (two had RIC, one had ATG only and one had myeloablative conditioning). In the three patients who are alive, only two are free of disease, and both had myeloablative conditioning with CY and TBI and had the second transplant at 9 and 21 months after the first transplant, suggesting that the longer waiting period between the two transplants may favorably affect the outcome. Very few patients are however stable enough to wait longer periods of time for the second SCT. For patients with FA, we previously reported successful matched related second SCT in three patients, using ATG only for reconditioning. 31 We used this approach in two FA patients in this series, one of whom engrafted but died of intracranial bleeding at 2 months after the transplant, and the other failed to engraft and remains alive with disease.
In conclusion, the results of UCB transplant in Saudi patients with cord blood units procured from western banks are encouraging and match reported results in western countries. The prompt availability of compatible units for our Saudi patients in international banks is probably due to the increased targeted recruitment of units from non-Caucasian donors. Currently, the national Saudi cord blood bank has 1650 unrelated units ready and the number is expected to go up to 5000 units over the next 3 years. With the extent of consanguinity in the Saudi society, we expect a higher degree of HLA matching that would be reflected in lower morbidity and longer survival.
